GlobeNewswire by notified

Valberedning utsedd inför årsstämman 2022 i Infant Bacterial Therapeutics (IBT).

Dela

Stockholm, 29 oktober 2021. Styrelsens ordförande i IBT har etablerat en valberedning inför årsstämman, som avses hållas den 4 maj 2022. Ledamöterna har utsetts av IBTs, i förhållande till röstetalet, tre största ägare, i enlighet med årsstämmans beslut 2021, vilka samtliga angivet att de önskat utse en ledamot i valberedningen.

Följande aktieägare var enligt aktieboken i IBT per den 30 juni 2021, till röstetalet, de tre största aktieägarna och de har utsett följande ledamöter:
Annwall & Rothschild Investments AB: Per-Erik Andersson
Six Sis AG: Sebastian Jahreskog
Fjärde AP-fonden: Jannis Kitsakis

Per-Erik Andersson blir ordförande i valberedningen i egenskap av ledamot utsedd av den störste aktieägaren i IBT.

Ovan angivna aktieägare representerar tillsammans cirka 27 procent av aktierna och 44 procent av rösterna i bolaget. Samtliga ledamöter i valberedningen, förutom Peter Rothschild, är oberoende i förhållande till bolaget och bolagsledningen.

Valberedningens uppgift är att till årsstämman lämna förslag till; val av ordförande på årsstämman, val av ordförande och övriga ledamöter i styrelsen, val av revisorer samt arvode och annan ersättning till styrelseledamöter och revisorer.

Aktieägare som vill lägga fram förslag till valberedningen kan göra detta via e-post till valberedningens ordförande: pea@pealaw.se
eller på telefon +46 (0)70 537 98 92.

För mer information, vänligen kontakta
Marie-Louise Alamaa, Ekonomidirektör
Tel. +46 (0) 70 861 88 42
Email: marie-louise.alamaa@ibtherapeutics.com

Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 29 oktober 2021, klockan 16.15 CET.

Om Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (”IBT”) är ett publikt bolag med säte i Stockholm. Bolagets aktier av serie B handlas på Nasdaq Stockholm, Mid Cap (IBT B).

Infant Bacterial Therapeutics AB (publ) (“IBT”) är ett läkemedelsföretag med en produkt i klinisk utvecklingsfas III, vars vision är att utveckla läkemedel som påverkar spädbarns mikrobiom och därigenom kunna förebygga eller behandla sällsynta sjukdomar som drabbar spädbarn.

IBT är för närvarande inriktat på att utveckla läkemedelskandidaten IBP-9414. Ambitionen med IBP-9414 är att bli världens första godkända probiotiska läkemedel med målsättning att förhindra livshotande spädbarnssjukdomar inklusive NEC och sepsis genom att främja en sund mag-och tarmutveckling hos för tidigt födda barn. IBP-9414 innehåller Lactobacillus reuteri som aktiv substans, vilket är en human bakteriestam som återfinns naturligt i bröstmjölk. I portföljen finns även ett ytterligare projekt, IBP-1016, för behandling av gastroschisis, en allvarlig och sällsynt sjukdom som drabbar spädbarn. Genom utvecklingen av dessa läkemedel har IBT möjlighet att tillfredsställa medicinska behov där det idag inte finns några tillgängliga behandlingar.

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Connecterra and Lely Announce Strategic Partnership2.12.2021 15:05:00 CET | Press release

Following the completion of a successful pilot, the two companies will deepen their collaboration and commercial relationship Amsterdam, The Netherlands, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Today Dutch-based startup, Connecterra, a world leader in using artificial intelligence to deliver insights to farmers, and Lely, the global leading supplier of robotics and management systems for dairy farming, announced the start of a robust co-development and commercial partnership. The announcement follows a pilot with Lely’s Digital Farming Group. The pilot program was designed to test an integration between Lely Horizon and Connecterra’s artificial intelligence platform, Ida. The successful effort has resulted in commitments to several strategic initiatives. As a first step in the agreement, Lely will now license Ida Enterprise for use in their farm management system Lely Horizon. “We believe that digitization of dairy farming is key and needs to be handled with care. Integrating with partners l

Fobi Announces Signing Of Amazon Fulfillment And Business Seller Agreement2.12.2021 13:45:00 CET | Press release

Fobi’s hardware and software solutions will now be available on Amazon Business, reaching over five million businesses worldwide VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. Inc.(FOBI:TSXV FOBIF:OTCQB) (the “Company” or “Fobi”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, announced it has signed an agreement with Amazon for distribution and fulfillment of Fobi AI’s various hardware products. As part of the agreement, Fobi will also become an Amazon Business Seller which will enable Fobi to gain access to Amazon’s global e-commerce, logistics and fulfillment infrastructure. By joining Amazon Business, Fobi immediately reaches over 5 million business customers in nine countries: a network that Fobi is very proud to now be included in. Fobi will now generate additional revenue through hardware, products and services sold on Amazon Business. Fobi will be launching their Fobi 3.0 I

Mandalay Resources Corporation Completes Sale of Cerro Bayo Mine to Equus Mining2.12.2021 13:30:00 CET | Press release

TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce that it has completed the previously announced sale of its Cerro Bayo mine in Region XI, Southern Chile (see Mandalay press releases dated October 12, 2021, and October 8, 2019). Pursuant to the transaction, Equus Mining Limited (“Equus”) acquired the Cerro Bayo mine, including its mining properties, resources and mine infrastructure as well as a 1,500 tonnes per day processing plant, in exchange for 587,502,438 ordinary shares in the capital of Equus. Mandalay also retains a 2.25% net smelter royalty on production from the Cerro Bayo mining claims once the mine has produced at least 50,000 ounces of gold equivalent, subject to a re-purchase option in favour of Equus, and remains responsible for 50% of approved site closure costs at Cerro Bayo. In addition, Equus will appoint Ryan Austerberry, Mandalay’s Costerfield mine General Manager

CTG and Micro Focus Extend European Platinum Partnership to French Market2.12.2021 12:55:00 CET | Press release

PARIS, Dec. 02, 2021 (GLOBE NEWSWIRE) -- CTG (NASDAQ: CTG), a leading provider of digital IT services and solutions in North America and Western Europe, today announced an expanded strategic partnership agreement with Micro Focus to now include CTG France. The partnership aligns CTG’s testing capabilities with Micro Focus’ Application Lifecycle Management (ALM) software to help clients accelerate their software delivery and ensure quality and application performance at every stage of the digital application lifecycle. Leveraging the global organization’s decades of experience, a team of more than 500 testers, and a network of more than 3,000 crowdtesters, CTG France offers its clients comprehensive Application Testing Solutions. The Company’s Testing Solutions portfolio includes advisory consulting, test methodology and process, performance testing, manual functional testing, testing automation, test tool implementation, and crowdtesting. Many of CTG’s more than 400 clients use Micro F

WESTPAY AND EASYCASHIER COMPLETE SUCCESSFUL LAUNCH OF MULTI-USER PAYMENT SOLUTION2.12.2021 12:45:00 CET | Press release

Westpay AB, a leading fintech company, has enabled multi-user functionality (MultiTID) in their payment application. This solution makes it possible for several users to share a physical payment solution. This is in demand in several verticals, such as hairdressers, who share premises but run their business individually. EasyCashier, a leading POS provider and a close partner to Westpay will be the first partner that offer this solution for their customers. - Again, I am proud that Westpay continues to push the limits to what you can expect from a payment solution.We have seen this functionality before, but the way we manage to simplify the use of sharing payment solutions. It is also happy that EasyCashier embraces this solution and enables it for their customers. They are a solid, reliable partner with great expertise and experience, says Hans Edin, CCO at Westpay. - Quality and innovation are two vital features for us at EasyCashier. We always try to level up the value as well as th

TGS Share Repurchase2.12.2021 10:57:49 CET | Press release

Oslo, Norway (02 December 2021) – On period from 25 November 2021 to 01 December 2021, TGS ASA (TGS) purchased 67,328 own shares on the Oslo Stock Exchange at an average price of NOK 85.1890 per share. Following the purchase TGS owns 1,226,303 shares, representing 1.044% of the total outstanding shares. The shares were purchased in connection with the share repurchase announced on 11 February 2021. Overview of transactionsDateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)25-Nov-2110,87888.9977968,11726-Nov-2120,00084.97931,699,58629-Nov-212,00084.2400168,48030-Nov-2120,00084.16361,683,2721-Dec-2114,45084.16241,216,147Previously disclosed buy-backs under the program (accumulated)1,143,975105.5774120,777,940Accumulated under the buy-back program1,211,303104.4442126,513,541The issuer's holding of own shares:Following the completion of the above transactions, TGS owns a total of 1,226,303 own shares, corresponding to

AB Linas Agro Group investors calendar for the 20222.12.2021 10:41:10 CET | Press release

A list of key information disclosure dates in 2022: February 28, 2022Interim half-year unaudited report for FY 2021/2022.March 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for the half-year of FY 2021/2022.May 31, 2022Interim unaudited report for 9 months of FY 2021/2022.June 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 9 months of FY 2021/2022.August 31, 2022Interim unaudited report for 12 months of FY 2021/2022.September 2, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 12 months of FY 2021/2022.Week 40 (Oct 3-7, 2022)Notice on Annual General Meeting of shareholders.Week 43 (Oct 24-28, 2022) Resolutions of the Annual General Meeting of shareholders and Annual audited results for FY 2021/2022.November 30, 2022Interim unaudited report for 3 months of 2022/2023 financial year.December 1, 2022Investor Conference Webinar to introduce unaudited financial an